Evidence-Based Reviews

Second-generation long-acting injectable antipsychotics: A practical guide

Author and Disclosure Information

 

References

Start with an oral antipsychotic

Before starting any LAIA, patients should receive the oral formulation of that antipsychotic to establish tolerability.1-7 Four of the 7 available LAIAs have an oral-to-LAI dose equivalency recommendation in their prescribing information (Table 22,5-7). This can help clinicians estimate the LAIA maintenance dose required to control a patient’s symptoms. If a dose adjustment is needed once a patient starts an LAIA, the dose adjustment can be made when the next injection is due.2

Oral-to-LAI dose equivalency recommendations

There are 2 important considerations when prescribing olanzapine pamoate LAI. First, the recommended dose for olanzapine pamoate LAI based on oral olanzapine doses differs during the first 8 weeks of treatment compared with after 8 weeks of treatment (Table 22,5-7). Additionally, because there are both short-acting and long-acting injections of olanzapine, it is essential to choose the correct formulation when prescribing this medication.5

Overlap with an oral antipsychotic might be necessary

Administration of several of the LAIAs may require overlap with an oral antipsychotic (Table 31,2,4-7). Patients who refuse to take oral medications may benefit from one of the LAIAs that does not require oral overlap—paliperidone palmitate monthly injection, olanzapine pamoate LAI, and risperidone LAI for SQ.2,5,7 Risperidone LAI requires overlap with oral risperidone for 3 weeks.1

Is overlap with an oral antipsychotic needed?

Aripiprazole is available in 2 LAI formulations: aripiprazole LAI and aripiprazole lauroxil LAI. Aripiprazole lauroxil is a prodrug of aripiprazole, and these 2 LAI medications differ in available dose options and dosing frequency.4,6 Aripiprazole LAI requires an oral overlap for 2 weeks after the first injection, whereas aripiprazole lauroxil LAI requires 3 weeks of oral overlap unless aripiprazole lauroxil 675-mg LAI is administered (Figure6).4,6,10

Initiating aripiprazole lauroxil long-acting injectable

Aripiprazole lauroxil 675-mg LAI is formulated with drug particles that are smaller than those in aripiprazole lauroxil LAI.11 The smaller particle size results in faster dissolution and a more rapid increase in plasma aripiprazole levels. Aripiprazole lauroxil 675-mg LAI is a single injection that should be given with one 30-mg dose of oral aripiprazole.10 This combination results in aripiprazole concentrations that are comparable to aripiprazole lauroxil LAI and oral aripiprazole overlap for 3 weeks after the first injection.10

Continue to: The starting dose of aripiprazole lauroxil LAI...

Pages

Recommended Reading

Top research findings of 2018-2019 for clinical practice
MDedge Psychiatry
Lumateperone for schizophrenia
MDedge Psychiatry
Therapeutic drug monitoring of antipsychotics
MDedge Psychiatry
Understanding postpartum psychosis: From course to treatment
MDedge Psychiatry
Cardiovascular disease risk higher in patients with schizophrenia, metabolic syndrome
MDedge Psychiatry
Early cognitive screening is key for schizophrenia spectrum disorder
MDedge Psychiatry
Cigarette smoking is associated with prefrontal function in patients with schizophrenia
MDedge Psychiatry
TNF-alpha, oxidative stress disturbance may play role in schizophrenia pathophysiology
MDedge Psychiatry
Severe infection tied to substance-induced psychosis, conversion to schizophrenia
MDedge Psychiatry
Transporting the high-risk psychiatric patient: Clinical and legal challenges
MDedge Psychiatry